FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280643539> ?p ?o ?g. }

• W4280643539 endingPage "215719" @default.
• W4280643539 startingPage "215719" @default.
• W4280643539 abstract "Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung cancer (SCLC) is slow. Extensive-stage SCLC (ES-SCLC) is a serious threat to human health, with a 5-year survival rate of <7%. Chemotherapy has been the first-line treatment for the past 30 years. The anti-PD-L1 checkpoint blockades durvalumab and atezolizumab have greatly prolonged overall survival and have become the standard first-line therapy for ES-SCLC since the CASPIAN and IMpower133 trials. In the era of chemotherapy, radiation therapy (RT), including thoracic radiation therapy (TRT) and brain radiation therapy (BRT), has shown clinical effects in randomized and retrospective studies on ES-SCLC. RT-immunotherapy has shown exciting synergistic effects in NSCLC. For ES-SCLC, the clinical effects of combining TRT/BRT with immunotherapy have not yet been systematically explored. In this review, we found that studies on RT-immunotherapy in ES-SCLC are relatively few and limited to early phase studies focusing on toxicity. The efficacy and safety profiles of early phase studies encourage prospective clinical trials. In this review, we discuss the best population, optimum TRT dose, proper TRT time, and strategies for reducing radiation-induced neurotoxicity. Furthermore, we suggest that biomarkers and patient performance status should be fully assessed before RT-immunotherapy treatment. Prospective trials are needed to provide more evidence for RT-immunotherapy applications in ES-SCLC." @default.
• W4280643539 created "2022-05-22" @default.
• W4280643539 creator A5000616499 @default.
• W4280643539 creator A5017134771 @default.
• W4280643539 creator A5024179763 @default.
• W4280643539 creator A5025275209 @default.
• W4280643539 creator A5045959882 @default.
• W4280643539 creator A5060446712 @default.
• W4280643539 creator A5080757739 @default.
• W4280643539 creator A5082684637 @default.
• W4280643539 date "2022-08-01" @default.
• W4280643539 modified "2023-10-10" @default.
• W4280643539 title "Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy" @default.
• W4280643539 cites W1516844956 @default.
• W4280643539 cites W1547463098 @default.
• W4280643539 cites W1910638072 @default.
• W4280643539 cites W1966470979 @default.
• W4280643539 cites W2002170698 @default.
• W4280643539 cites W2031170553 @default.
• W4280643539 cites W2048869426 @default.
• W4280643539 cites W2057918332 @default.
• W4280643539 cites W2101751898 @default.
• W4280643539 cites W2130927837 @default.
• W4280643539 cites W2131664752 @default.
• W4280643539 cites W2138683149 @default.
• W4280643539 cites W2141604895 @default.
• W4280643539 cites W2148554106 @default.
• W4280643539 cites W2154323253 @default.
• W4280643539 cites W2155599713 @default.
• W4280643539 cites W2158651762 @default.
• W4280643539 cites W2189143821 @default.
• W4280643539 cites W2287384543 @default.
• W4280643539 cites W2404288963 @default.
• W4280643539 cites W2480201404 @default.
• W4280643539 cites W2512217706 @default.
• W4280643539 cites W2519738089 @default.
• W4280643539 cites W2524122718 @default.
• W4280643539 cites W2557717931 @default.
• W4280643539 cites W2592145077 @default.
• W4280643539 cites W2598659203 @default.
• W4280643539 cites W2599941031 @default.
• W4280643539 cites W2642802273 @default.
• W4280643539 cites W2750137673 @default.
• W4280643539 cites W2753004811 @default.
• W4280643539 cites W2753065806 @default.
• W4280643539 cites W2756666776 @default.
• W4280643539 cites W2762059365 @default.
• W4280643539 cites W2766844136 @default.
• W4280643539 cites W2769061899 @default.
• W4280643539 cites W2771966188 @default.
• W4280643539 cites W2782652081 @default.
• W4280643539 cites W2785312166 @default.
• W4280643539 cites W2787666307 @default.
• W4280643539 cites W2788208686 @default.
• W4280643539 cites W2790853889 @default.
• W4280643539 cites W2800252028 @default.
• W4280643539 cites W2810165177 @default.
• W4280643539 cites W2816152715 @default.
• W4280643539 cites W2886119834 @default.
• W4280643539 cites W2888008084 @default.
• W4280643539 cites W2888123370 @default.
• W4280643539 cites W2893824814 @default.
• W4280643539 cites W2893960509 @default.
• W4280643539 cites W2913123185 @default.
• W4280643539 cites W2913728083 @default.
• W4280643539 cites W2915501822 @default.
• W4280643539 cites W2916875443 @default.
• W4280643539 cites W2947249562 @default.
• W4280643539 cites W2949868092 @default.
• W4280643539 cites W2954542121 @default.
• W4280643539 cites W2954842230 @default.
• W4280643539 cites W2966905990 @default.
• W4280643539 cites W2968490685 @default.
• W4280643539 cites W2972618064 @default.
• W4280643539 cites W2977392388 @default.
• W4280643539 cites W2979920955 @default.
• W4280643539 cites W2980537150 @default.
• W4280643539 cites W2998778146 @default.
• W4280643539 cites W3004615369 @default.
• W4280643539 cites W3006467062 @default.
• W4280643539 cites W3012661873 @default.
• W4280643539 cites W3014209163 @default.
• W4280643539 cites W3026701087 @default.
• W4280643539 cites W3029678115 @default.
• W4280643539 cites W3030178583 @default.
• W4280643539 cites W3030999222 @default.
• W4280643539 cites W3040100953 @default.
• W4280643539 cites W3084346982 @default.
• W4280643539 cites W3084355783 @default.
• W4280643539 cites W3086650356 @default.
• W4280643539 cites W3087788304 @default.
• W4280643539 cites W3092159910 @default.
• W4280643539 cites W3110002524 @default.
• W4280643539 cites W3117633542 @default.
• W4280643539 cites W3120634002 @default.
• W4280643539 cites W3126784591 @default.
• W4280643539 cites W3165174350 @default.
• W4280643539 cites W3187697046 @default.

• next